Matter Neuroscience: A Brainy Investment
March 5, 2024, 2:32 am
Matter Neuroscience, a NYC-based company focused on providing personalized insights into brain chemistry, recently secured a hefty $26 million in funding. The company, founded in 2019 by Axel Bouchon, Ben Goldhirsh, and Chris Shiflett, aims to leverage neuroscience to help individuals improve their health and happiness.
The funding round, which included investments from Polaris Partners, ARCH Venture Partners, Exor Ventures, and Collaborative Fund, will be used to further develop Matter Neuroscience's solutions. The company has already released an early version of its public beta app, designed to help users record and reflect on positive experiences, understand neurotransmitter activity, and make positive changes in their daily lives.
Matter Neuroscience's mission is to address the unhappiness epidemic by transforming our understanding and management of mental well-being. With a team led by CEO Axel Bouchon, COO Bridget Best, and Chairman Ben Goldhirsh, Matter Neuroscience is poised to make a significant impact on the field of neuroscience and mental health.
In a world where happiness and well-being are increasingly valued, Matter Neuroscience's innovative approach to brain chemistry and personalized insights is a smart investment for those looking to improve their quality of life. With this recent funding, Matter Neuroscience is well-positioned to continue pioneering solutions that help individuals live longer, healthier, and happier lives.
The funding round, which included investments from Polaris Partners, ARCH Venture Partners, Exor Ventures, and Collaborative Fund, will be used to further develop Matter Neuroscience's solutions. The company has already released an early version of its public beta app, designed to help users record and reflect on positive experiences, understand neurotransmitter activity, and make positive changes in their daily lives.
Matter Neuroscience's mission is to address the unhappiness epidemic by transforming our understanding and management of mental well-being. With a team led by CEO Axel Bouchon, COO Bridget Best, and Chairman Ben Goldhirsh, Matter Neuroscience is poised to make a significant impact on the field of neuroscience and mental health.
In a world where happiness and well-being are increasingly valued, Matter Neuroscience's innovative approach to brain chemistry and personalized insights is a smart investment for those looking to improve their quality of life. With this recent funding, Matter Neuroscience is well-positioned to continue pioneering solutions that help individuals live longer, healthier, and happier lives.